Guardant Health (GH) is back in focus after the U.S. Food and Drug Administration approved its Guardant360 CDx liquid biopsy as a companion diagnostic for Boehringer Ingelheim’s newly approved HERNEXEOS lung cancer therapy.

The recent FDA approval arrives as momentum in Guardant Health's stock has been strong, with a 90-day share price return of 55.58% and a 1-year total shareholder return of 174.69%. This indicates that investors are reassessing both growth prospects and risks.

If you are interested in how other cancer and diagnostics companies tied to artificial intelligence are trading, this is a good moment to scan the market using the 38 healthcare AI stocks

With Guardant Health now trading close to published analyst targets and carrying an indicated intrinsic discount of about 16%, the key question is whether the recent FDA win leaves meaningful upside or whether the market is already pricing in future growth.

Most Popular Narrative: 1% Overvalued

The most widely followed narrative currently places Guardant Health's fair value at $135.76, slightly below the last close at $137.07, so the margin for error is tight and hinges on ambitious growth and profitability assumptions.

Analysts expect earnings to reach $4.4 million (and earnings per share of $0.16) by about June 2029, up from $433.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $140.5 million in earnings, and the most bearish expecting $253.5 million.

Curious what kind of revenue curve, margin path, and share count changes could support that valuation gap and future earnings bridge for Guardant Health? The most popular narrative leans on faster top line expansion, improving profitability, and a very rich future earnings multiple to justify its fair value. The precise mix of those assumptions is where the real story sits.

Result: Fair Value of $135.76 (OVERVALUED)

However, Guardant Health’s story could shift quickly if high R&D spending prolongs losses or if reimbursement and payer adoption for Shield and other tests fall short of expectations.

Another View on Guardant Health’s Valuation

The analyst narrative frames Guardant Health as about 1% overvalued at a fair value of $135.76, but the SWS DCF model points in the opposite direction. On that approach, GH at $137.07 is trading roughly 16% below an estimated future cash flow value of $162.43. Which lens should carry more weight for you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Guardant Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and concern around Guardant Health feels finely balanced, take the time to review the facts for yourself and weigh both sides with the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Guardant Health?

If Guardant Health has sharpened your interest in growth stories, do not stop here. Use the Simply Wall Street Screener to compare fresh opportunities side by side.

• Spot potential mispricings early by reviewing 44 high quality undervalued stocks, which combine quality fundamentals with market pessimism that might not match the underlying numbers.
• Focus on resilience by scanning 70 resilient stocks with low risk scores, where balance sheets, earnings quality, and risk scores point to businesses that may handle setbacks more steadily.
• Stay informed by checking the screener containing 18 high quality undiscovered gems, which highlight quieter stories before they attract broader interest.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.